Search results

Purpose – This study is intended to extend scholarship on the management of organizations by examining the long-term performance of orphaned products.

Design/methodology/approach – This study uses the historical context of the 1929 stock market crash and the Great Depression to examine the long-run appeal (performance) of orphaned products – products from start-ups that fail soon after production. I use this setting to determine how factors within the purview of management, as well as the role of changing tastes, affect the appeal of music from short-lived start-ups founded in 1929 and 1933.

Findings/originality/value – I find that while the evolution of tastes has a substantial effect beyond the control of a firm's managers, a start-up's decision-makers were able to positively influence the long-run appeal of music when they (a) recorded tunes with new artists and (b) were able to create an early big hit with the tune. These results demonstrate how and why, even with cultural producers in one of the greatest economic disasters in U.S. history, managerial decisions were meaningful for product performance. Finally, I show that the effect of being a start-up on the long-run appeal of a tune is time-varying such that being a start-up in 1929 or 1933 does not harm a tune's appeal until after World War II. These final analyses point to further ways in which strategy, history, and sociology might combine to further scholarship on the management of organizations.

Manufacturers find bottom of the pyramid (BOP) markets challenging to serve due to low margins and highly localized needs. As such, residents in BOP markets often go without products commonly available in developed countries. Going without medical equipment may negatively affect healthcare services. This study develops a supply chain design strategy that supports the production of medical equipment by preserving variety flexibility at low volumes that stands to create new market opportunities for manufacturers and improve healthcare for residents in BOP markets.

The authors introduce a mass-customization model called options-based planning (OBP) which offers a framework to both leverage the efficiencies of high volume production models and provide products that are customized to local market needs. An empirical simulation, grounded in data collected from a large international manufacturer of magnetic resonance imaging (MRI) equipment, illustrates how an OBP production strategy will likely perform under BOP conditions and facilitate the delivery of healthcare equipment to BOP markets.

OBP provides a means for manufacturers to provide the customization necessary to serve fragmented BOP markets, while enabling higher production volume to make serving these markets more feasible. The empirical simulation reveals the relative benefits of OBP under conditions of forecast uncertainty, product complexity (number of design parameters) and different levels of responsiveness.

Increased access to modern medical equipment should improve healthcare outcomes for consumers in BOP markets.

The MRI context in BOP markets serves to illustrate the value of the OBP model for manufacturers.

This article aims to provide a description of principal aspects of policy and practice associated with orphan drugs and treatments of rare diseases, and give perspectives for 2011 on new and emerging approaches for addressing patient access.

Information has been synthesized from a wide variety of sources including the authors' experience and familiarity with this topic, having over the past ten years developed market access strategies for many orphan drugs. This is supplemented by pertinent information from conferences, meetings and articles published over the last 20 years and from policy documents released by relevant regulatory bodies.

While a small number of people suffer from any one rare disease, approximately 30 million in the EU and 25 million in the USA are affected by such diseases. Annual orphan drug treatment costs may approach $500,000. High costs coupled with relatively sparse supportive clinical data and difficulty in meeting standard cost‐effectiveness benchmarks raise significant issues for payers in allocating finite budgetary resources. Since the US (1983) and European (European Parliament, 2000) orphan drug regulations were approved, hundreds of agents have been granted orphan status although many fewer have achieved marketing authorization. Agencies have introduced a slew of incentives to help sponsors develop and market orphan medicinal products. The nature and focus of the programs are undergoing a metamorphosis as access to funding is becoming as important as supporting development.

The article represents a contemporary examination of orphan drug policy and practice, bringing together historic elements which influenced practice up to 2010 and the latest, emerging trends and approaches which stakeholders are now embracing and which will shape procedures from 2011.

Purpose – This chapter is intended to identify the actual and potential linkages between history and strategy research.

Design/methodology/approach – Drawing on examples from research at the intersection of history and strategy, we identify research topics that have received attention from a historical-strategy lens, and those that are thus far understudied. We then place the studies that appear in this volume into their relevant context.

Findings – The chapter outlines benefits that the strategy field can gain from a greater emphasis on history, and that the history field can gain from a greater use of strategic insights.

Originality/value – The chapter sets the context for the studies in this volume, and provides a lens for evaluating the benefits of historical-strategy research.

The purpose of this paper is to show the link between the comparative effectiveness research (CER) and the interest in developing drugs for rare disease by the pharmaceutical industry. Total healthcare spending is on the rise without having a corresponding better health outcome. As such, with the growing role of government in healthcare, measuring and demonstrating value is beginning to expand beyond the private sector to metrics applied in the public sector. A modern approach to comparative effective research began its rapid rise in the USA when the American Recovery and Reinvestment Act of 2009 allocated $1.1 billion for CER. This paper analyzes the implication and impact on the pharmaceutical industry.

The paper reviews the basic definitions of CER and its areas of strength and weakness. It used real examples of drugs to show the impact of the Reinvestment Act of 2009 on the rise of orphan drugs.

The study shows that the act encouraged the development of orphan drugs, mainly because of the low budget impact due to a smaller patient base. Provisions of the Affordable Care Act provide incentives for such rare disease indications, as no one can be denied coverage with pre-existing conditions.

The study is limited by the number of available rare drugs and the ongoing process of implementation of the Affordable Care Act.

The study shows the cost-effective method of treating medical conditions.

Development of orphan drugs opens up access to care for many patients at a cost-effective price.

This paper shows the link between the CER and the interest in developing drugs for rare disease by the pharmaceutical industry. It also brings out the possible implication of the Affordable Care Act on the pharmaceutical industry with respect to its strategies for drug development and drug portfolio.

Purpose – This chapter traces the creation of a market for strategy by management consulting firms during the second half of the twentieth century in order to demonstrate their impact in shaping debates in the subject and demand for their services by corporate executives.

Design/methodology/approach – Using historical analysis, the chapter draws on institutional theory, including institutional isomorphism. It uses both primary and secondary data from the leading consulting firms to describe how consultants shifted from offering advice on organizational structure to corporate strategy and eventually to corporate legitimacy as a result of the changing economic and regulatory environment of the time.

Findings/originality/value – This study provides a historical context for the emergence of corporate and competitive strategy as an institutional practice in both the United States and around the world, and provides insights into how important this history can be in understanding the debates among consultants and academics during strategy's emergence as an academic subject and practical application.

The field of transportation research, and the World Conferences on Transport Research Society (WCTRS), has an illustrious history. The challenge today is to look to the future in a deep and thoughtful way, to identify emerging issues and opportunities for practice and for research.

This chapter identifies several critical issues in transportation research. We then explore one issue in depth, the need to increase individual and collaborative effectiveness.

This issue points to the need for a new direction in transportation research. Historically, transportation research has focussed on two major thrusts. The analysis thrust has focussed on predicting the consequences of a given transportation plan, project, or service proposal. Associated “design” research has dealt with algorithmic and heuristic techniques for finding “good” plans or policies. The policy thrust has focussed on the organizational issues and processes around making decisions on and implementing transportation plans, projects, or services. This thrust includes public policy issues and approaches, market structures and regulatory processes, organization design issues, distributional consequences, environmental policy issues, and related areas.

Today, we see the need to add a third major thrust to the field of transportation — cognition and action:

• to manage transportation services and enterprises better;

• to use analysis more effectively to inform and influence decisions;

• to use computer support more effectively in transportation organizations and enterprises.

to manage transportation services and enterprises better;

to use analysis more effectively to inform and influence decisions;

to use computer support more effectively in transportation organizations and enterprises.

Research in cognition and action examines how people think and act, and aims to develop aids to thinking and acting that result in significant improvements in peoples' behaviours and performance. Promising research directions draw on cognitive psychology and cognitive science, and especially empirical research on managerial cognition and problem-solving. We introduce the theory of cognitive informatics, describe some applications to transportation management, and discuss relevant software tools.

The present paper aims to understand the underpinnings of the variations in brand level direct‐to‐consumer (DTC) advertising through a two‐part study. First, it seeks to examine the various influences on advertising intensity (operationalized by advertising to sales ratios) in the context of DTC advertising. Second, it aims to analyze how changes in share of voice impact changes in market share.

Data on brand level advertising as well as sales were collected from different government and industry sources. This is used to compute the ratio of DTC advertising to sales as well as changes in share of voice, market share and average drug prices. A log‐log model is used to find parameter estimates based on OLS regression.

Market share has a negative influence on the ratio of advertising to sales. Drugs which have a greater degree of innovation (as judged by the FDA) appear to spend more on DTC advertising relative to sales. The paper also finds that an increase in share of voice is not associated with increased average drug prices, but is related to a growth of market share because of a change in the share of total prescriptions dispensed.

The paper is one of the few to examine the factors influencing advertising to sales ratios in the context of DTC advertising. It is also one of the first to investigate the relationship of changes in the share of voice with changes in market share.

Increasing awareness of man's impact on the environment and pressure to behave in a more sustainable manner are encouraging both the recycling and reuse of materials and the replacement of hazardous chemicals with more benign ones. The Waste Electrical and Electronic Equipment (WEEE) Directive and the Restriction on the use of certain Hazardous Substances in Electrical and Electronic Equipment (RoHS) Directive, have recently been adopted into law with the specific intention of further encouraging these activities through legislation. In addition to these directives, there is a growing need to adopt sound design principles so that new products are created in a more environmentally acceptable way and that their environmental impact throughout their lifecycles is minimised. This paper gives an overview of this new European legislation and discusses its impact on the electronics industry. The potential benefits of adopting such an approach are outlined.